We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App




Mobile CT Platform Provides Diagnostic and Intraoperative Support

By Medimaging International staff writers
Posted on 16 Oct 2019
Print article
Image: The SeeFactorCT3 multi-modality, lightweight mobile CT platform (Photo courtesy of Epica International).
Image: The SeeFactorCT3 multi-modality, lightweight mobile CT platform (Photo courtesy of Epica International).
A multi-modality, lightweight mobile computerized tomography (CT) platform can be easily moved as needed between trauma, imaging, and operating room (OR) spaces.

The Epica International (San Clemente, CA, USA) SeeFactorCT3 system is a high definition volumetric imaging platform (HDVI) that delivers onboard three-dimensional (3D) CT, fluoroscopy, and digital radiography capabilities to all sections of a healthcare facility. The lightweight, maneuverable system includes a detachable patient table/chair, a sterile drape for interventional procedures, and the SeeFactor CT3 itself. Highly maneuverable, the system can be moved through normal sized doors and hallways to an ambulatory/outpatient center (ASC), the intensive care unit (ICU), ER/Trauma areas, imaging rooms, or the OR.

The SeeFactorCT3 platform utilizes a dynamic flat panel detector (FPD) sensor to acquire sequences of the head including ear, nose and throat (ENT), the teeth, mandible and jaw, temporo-mandibular joint (TMJ), other areas of human skull and neck with sections of upper cervical spine, and upper and lower extremities. Images can be displayed in both 2D and 3D for each examined anatomical region. Unlike conventional CT systems, the SeeFactorCT3 provides non-interpolated (slice-less) image data, delivering isotropic ultrafine image resolution (0.1mm) in both soft and hard tissue, lesion detection as small as 0.2mm, and significantly reduced radiation doses.

“I am very pleased to announce this major milestone event in Epica's history; our progression into the human medical space,” said Frank D'Amelio, CEO of Epica International. “What started five years ago as a multidisciplinary team of scientists, medical device engineers, robotics experts, and clinicians focused on improvement of CT imaging, led to the development of a robotically controlled, non- interpolated diagnostic and intraoperative imaging platform, capable of identifying anatomies as small as the vasculature of a hummingbird with less radiation dose and cost.”

Related Links:
Epica International


Print article
Radcal
CIRS

Channels

Copyright © 2000-2019 Globetech Media. All rights reserved.